One such Phase 2 clinical trial in patients with recurrent ovarian cancer (NCT02764333) combined TPIV200, a peptide vaccine composed of five immunogenic peptide epitopes of FRα, with durvalumab, a PD-L1 inhibitor antibody.110 Although treatment was well tolerated and increased early T cell responses were observed, only one patient demonstrated a partial response, and all patients ultimately progressed. This evidence concerns the gene FOLR1 and ovarian cancer.